TP 003CAS# 628690-75-5 |
- Preladenant
Catalog No.:BCC1868
CAS No.:377727-87-2
- ANR 94
Catalog No.:BCC7815
CAS No.:634924-89-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 628690-75-5 | SDF | Download SDF |
| PubChem ID | 10001434 | Appearance | Powder |
| Formula | C23H16F3N3O | M.Wt | 407.39 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 50 mM in ethanol | ||
| Chemical Name | 5-fluoro-2-[2-fluoro-5-[8-fluoro-7-(2-hydroxypropan-2-yl)imidazo[1,2-a]pyridin-3-yl]phenyl]benzonitrile | ||
| SMILES | CC(C)(C1=C(C2=NC=C(N2C=C1)C3=CC(=C(C=C3)F)C4=C(C=C(C=C4)F)C#N)F)O | ||
| Standard InChIKey | SJMMDWXJSSJHOQ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C23H16F3N3O/c1-23(2,30)18-7-8-29-20(12-28-22(29)21(18)26)13-3-6-19(25)17(10-13)16-5-4-15(24)9-14(16)11-27/h3-10,12,30H,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Functionally selective GABAA receptor (α3 subtype) partial agonist. Exhibits affinity for the benzodiazepine binding site on human GABAA receptors. Potentiates the GABA (α3 subtype) response selectively with high efficacy. Produces anxiolytic-like effects in rodent behavioral models of anxiety. |
TP 003 Dilution Calculator
TP 003 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4547 mL | 12.2733 mL | 24.5465 mL | 49.093 mL | 61.3663 mL |
| 5 mM | 0.4909 mL | 2.4547 mL | 4.9093 mL | 9.8186 mL | 12.2733 mL |
| 10 mM | 0.2455 mL | 1.2273 mL | 2.4547 mL | 4.9093 mL | 6.1366 mL |
| 50 mM | 0.0491 mL | 0.2455 mL | 0.4909 mL | 0.9819 mL | 1.2273 mL |
| 100 mM | 0.0245 mL | 0.1227 mL | 0.2455 mL | 0.4909 mL | 0.6137 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Senampeline B
Catalog No.:BCN2031
CAS No.:62860-52-0
- 2-Amino-6-nitrobenzothiazole
Catalog No.:BCC8544
CAS No.:6285-57-0
- Senampeline E
Catalog No.:BCN2032
CAS No.:71075-42-8
- Meglumine
Catalog No.:BCC4795
CAS No.:6284-40-8
- Jolkinol A
Catalog No.:BCN3778
CAS No.:62820-11-5
- Palmitic acid ethyl ester
Catalog No.:BCN8298
CAS No.:628-97-7
- SU14813
Catalog No.:BCC1971
CAS No.:627908-92-3
- Senampeline D
Catalog No.:BCN2033
CAS No.:62787-01-3
- Senampeline A
Catalog No.:BCN2030
CAS No.:62787-00-2
- Pterophorine
Catalog No.:BCN2118
CAS No.:62786-99-6
- Epitrametol
Catalog No.:BCN7073
CAS No.:627538-65-2
- SD-208
Catalog No.:BCC1938
CAS No.:627536-09-8
- Hecubine
Catalog No.:BCN7467
CAS No.:62874-52-6
- Cefoperazone
Catalog No.:BCC3748
CAS No.:62893-19-0
- Heptanal oxime
Catalog No.:BCN2267
CAS No.:629-31-2
- Procaterol hydrochloride
Catalog No.:BCC6937
CAS No.:62929-91-3
- H-D-Pro-NH2
Catalog No.:BCC3024
CAS No.:62937-45-5
- Kuwanon A
Catalog No.:BCN2944
CAS No.:62949-77-3
- Mulberrin
Catalog No.:BCN4167
CAS No.:62949-79-5
- Morusinol
Catalog No.:BCN4168
CAS No.:62949-93-3
- 6-Methoxy-4-methylcoumarin
Catalog No.:BCN6537
CAS No.:6295-35-8
- (2-Benzothiazolylthio)acetic acid
Catalog No.:BCC8387
CAS No.:6295-57-4
- Gomisin F
Catalog No.:BCN3625
CAS No.:62956-47-2
- Gomisin G
Catalog No.:BCN2269
CAS No.:62956-48-3
Contribution of GABA(A) receptors containing alpha3 subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys.[Pubmed:21190016]
Psychopharmacology (Berl). 2011 May;215(2):311-9.
RATIONALE: Experimental evidence suggests that the differential behavioral effects of benzodiazepines depend on their relative actions at gamma-aminobutyric acid type A (GABA(A)) receptors that contain either an alpha1, alpha2, alpha3, or alpha5 subunit. OBJECTIVES: The present study was aimed at understanding the role of alpha3 subunit-containing GABA(A) (alpha3GABA(A)) receptors by examining the behavioral pharmacology of TP003 (4,2'-difluoro-5'-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo[1,2-a]pyridine-3-y l]biphenyl-2-carbonitrile), which shows functional selectivity for alpha3GABA(A) receptors. METHODS: First, a conflict procedure was used to assess the anxiolytic-like effects of TP003 and a representative clinically available benzodiazepine. TP003 was also administered before daily periods of sucrose pellet availability to evaluate potential hyperphagic effects. In separate experiments, observable behavioral effects were used to assess the motor and sedative effects of TP003. RESULTS: Administration of TP003 produced robust anti-conflict effects without the rate-decreasing effects that were observed with the representative benzodiazepine. Unlike the reported effects of benzodiazepines, TP003 did not enhance palatable food consumption. However, increases in observable sleep-associated posture were induced by TP003, as were decreases in some species-typical behaviors (vocalization, locomotion, and environment-directed behaviors). When evaluated for its ability to induce a procumbent posture, TP003 failed to produce an effect. CONCLUSIONS: Based on conflict and observation tests in monkeys, our results suggest that TP003 may have anxiolytic properties but lack ataxic, hyperphagic, and pronounced sedative effects characteristic of classical benzodiazepines. TP003 did induce myorelaxant-like effects and had relatively mild sedative effects. Collectively, these results suggest that alpha3GABA(A) receptors play an important role in the anxiolytic-like and motor effects of benzodiazepine-type drugs.
Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines.[Pubmed:16291941]
J Neurosci. 2005 Nov 16;25(46):10682-8.
The GABA(A) receptor subtypes responsible for the anxiolytic effects of nonselective benzodiazepines (BZs) such as chlordiazepoxide (CDP) and diazepam remain controversial. Hence, molecular genetic data suggest that alpha2-rather than alpha3-containing GABA(A) receptors are responsible for the anxiolytic effects of diazepam, whereas the anxiogenic effects of an alpha3-selective inverse agonist suggest that an agonist selective for this subtype should be anxiolytic. We have extended this latter pharmacological approach to identify a compound, 4,2'-difluoro-5'-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo[1,2-a]pyridin-3-yl] biphenyl-2-carbonitrile (TP003), that is an alpha3 subtype selective agonist that produced a robust anxiolytic-like effect in both rodent and non-human primate behavioral models of anxiety. Moreover, in mice containing a point mutation that renders alpha2-containing receptors BZ insensitive (alpha2H101R mice), TP003 as well as the nonselective agonist CDP retained efficacy in a stress-induced hyperthermia model. Together, these data show that potentiation of alpha3-containing GABA(A) receptors is sufficient to produce the anxiolytic effects of BZs and that alpha2 potentiation may not be necessary.
